KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Invested Capital (2016 - 2025)

Acadia Pharmaceuticals has reported Invested Capital over the past 16 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Invested Capital at $1.2 billion for Q4 2025, up 67.49% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (up 67.49% YoY), and the annual figure for FY2025 was $1.2 billion, up 67.49%.
  • Invested Capital for Q4 2025 was $1.2 billion at Acadia Pharmaceuticals, up from $917.3 million in the prior quarter.
  • Over the last five years, Invested Capital for ACAD hit a ceiling of $1.2 billion in Q4 2025 and a floor of $362.2 million in Q3 2023.
  • Median Invested Capital over the past 5 years was $528.8 million (2021), compared with a mean of $577.4 million.
  • Biggest five-year swings in Invested Capital: dropped 25.97% in 2022 and later surged 69.72% in 2024.
  • Acadia Pharmaceuticals' Invested Capital stood at $540.9 million in 2021, then dropped by 25.97% to $400.4 million in 2022, then grew by 7.83% to $431.8 million in 2023, then surged by 69.72% to $732.8 million in 2024, then skyrocketed by 67.49% to $1.2 billion in 2025.
  • The last three reported values for Invested Capital were $1.2 billion (Q4 2025), $917.3 million (Q3 2025), and $822.4 million (Q2 2025) per Business Quant data.